Boerekamps A, et al. - In the Dutch Acute hepatitis C virus [HCV] in HIV study number 2 (DAHHS2) study, researchers evaluated the effectiveness of grazoprevir plus elbasvir treatment in acute HCV infection and investigated whether treatment can be shortened during the acute phase of HCV infection. In 15 HIV outpatient clinics in the Netherlands and Belgium, adult patients (≥18 years) with acute HCV genotype 1 or 4 infection were recruited. All patients were treated with 8 weeks of 100 mg grazoprevir plus 50 mg elbasvir once daily in a single oral fixed drug combination tablet. For the treatment of acute HCV genotype 1 or 4 infection, eight weeks of grazoprevir plus elbasvir was highly effective. The ability to treat acute HCV immediately after diagnosis could help doctors to achieve the WHO goal of eliminating HCV by 2030. Fatigue, headache, insomnia, mood changes, dyspepsia, concentration impairment, and dizziness were the most common reported possibly drug-related adverse events, all of which were regarded as mild by the treating physician.